FORMATO EUROPEO PER IL CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome	Stefano Goldwurm
Indirizzo	Centro Parkinson, ASST "Gaetano Pini/CTO" (ex Istituti Clinici di Perfezionamento) Via Bignami, 1; 20126 Milano
Telefono	02 5799 3319
Fax	02 5799 3468
E-mail	stefano.goldwurm@asst-pini-cto.it stefano.goldwurm@mail.com
Nazionalità	italiana
Data di nascita	26/03/1964
ORCID id	orcid.org/ 0000-0002-1651-567X

ESPERIENZA LAVORATIVA

• Date (da 1/1/2016 – a oggi)	Dal 1/1/2016 – a oggi
• Nome e indirizzo del datore di lavoro	ASST "Gaetano Pini/CTO" (ex Istituti Clinici di Perfezionamento) Centro Parkinson
• Tipo di azienda o settore	Servizio Sanitario Nazionale
• Tipo di impiego	Medico genetista all'Unità Operativa di Neurologia – Centro Parkinson e Disturbi del Movimento.
• Principali mansioni e responsabilità	Gestione delle consulenze genetiche e i test genetici nei casi di disturbi del movimento e nelle malattie neurodegnerative di probabile origine genetica, inclusa l'esecuzione di test genetici presintomatici.

• Date	Dal 1/9/2017 – a oggi
• Nome e indirizzo del datore di lavoro	Unità Operativa di Neurologia 2, Centro Parkinson Regionale Esperto – Città della Salute e della Scienza, Torino; Dipartimento di Neuroscienze "Rita Levi Montalcini", Università di Torino.
• Tipo di azienda o settore	Servizio Sanitario Nazionale
• Tipo di impiego	Medico genetista all'Unità Operativa di Neurologia-2.
• Principali mansioni e responsabilità	Gestione delle consulenze genetiche e i test genetici nei casi di disturbi del movimento e nelle malattie neurodegnerative di probabile origine genetica, inclusa l'esecuzione di test genetici presintomatici.

• Date (da – a)	*Dal 2002 al 2016*
• Nome e indirizzo del datore di lavoro	Istituti Clinici di Perfezionamento Centro Parkinson
• Tipo di azienda o settore	Azienda Ospedaliera Pubblica
• Tipo di impiego	Medico genetista all'Unità Operativa di Neurologia – Centro Parkinson e Disturbi del Movimento.

• Principali mansioni e responsabilità	Gestione delle consulenze genetiche e i test genetici nei casi di disturbi del movimento e nelle malattie neurodegnerative di probabile origine genetica, inclusa l'esecuzione di test genetici presintomatici.
• Date (da – a)	*Dal 1997 al 2002*
• Nome e indirizzo del datore di lavoro	Clinica Pediatrica dell'Università di Milano, Ospedale Nuovo San Gerardo di Monza
• Tipo di azienda o settore	Azienda Ospedaliera Pubblica
• Tipo di impiego	Medico specializzando in Genetica Medica presso la Clinica Pediatrica dell'Università di Milano, Ospedale Nuovo San Gerardo di Monza, responsabile Prof. Andrea Biondi.
• Principali mansioni e responsabilità	avviamento di un Laboratorio di Genetica Molecolare in grado di eseguire test diagnostici per malattie genetiche con tecniche molecolari e contemporaneamente fornire il risultato del test ai pazienti tramite la consulenza genetica.
• Date (da – a)	*1994-1997*
• Nome e indirizzo del datore di lavoro	Laboratorio di Genetica della "Liver Unit", Queensland Institute of Medical Research, University of Queensland Brisbane, Australia.
• Tipo di azienda o settore	Istituto di Ricerca Pubblico
• Tipo di impiego	Studente di PhD (Dottorato di Ricerca) alla University of Queensland presso il Laboratorio di Genetica della Liver Unit, Queensland Institute of Medical Research, Brisbane, Australia. Progetto di ricerca: Positional cloning of the haemochromatosis gene.
• Principali mansioni e responsabilità	Ricercatore

ISTRUZIONE E FORMAZIONE

• Date (da – a)	2017
• Nome e tipo di istituto di istruzione o formazione	Abilitazione Scientifica Nazionale per professore associato di seconda fascia (bando D.D. 1532/2016) nel settore concorsuale 06/A1-GENETICA MEDICA, valido dal 31/03/2017 al 31/03/2023 (art. 16, comma 1, Legge 240/10).
• Principali materie / abilità professionali oggetto dello studio	Insegnamento Genetica Medica.
• Qualifica conseguita	Abilitazione Scientifica Nazionale per professore associato di seconda fascia nel settore concorsuale 06/A1-GENETICA MEDICA, conferito dal MIUR.
• Livello nella classificazione nazionale (se pertinente)	
• Date (da – a)	1997-2001
• Nome e tipo di istituto di istruzione o formazione	Diploma di Specialità in Genetica Medica, 70/70 cum laude, Università degli Studi di Milano. Titolo della Tesi: "Analisi dello spettro mutazionale della mucopolisaccaridosi di tipo I nella popolazione italiana", relatore Prof. Andrea Biondi, correlatore Dr.sa Rossella Parini.
• Principali materie / abilità professionali oggetto dello studio	Specialità in Genetica Medica
• Qualifica conseguita	Diploma di Specialità in Genetica Medica
• Livello nella classificazione nazionale (se pertinente)	
• Date (da – a)	1994-1997
• Nome e tipo di istituto di istruzione o formazione	Doctor in Philosophy (PhD) in the field of Medicine, University of Queensland, Brisbane, Australia. (equiparato ad un Dottorato di Ricerca) Titolo della Tesi: "Identification and characterisation of haemochromatosis candidate genes", principal supervisor Dr. Elizabeth C. Jazwinska, second supervisor Prof. Lawrie W. Powell.
• Principali materie / abilità professionali oggetto dello studio	Molecular genetics.

• Qualifica conseguita	Doctor in Philosophy (PhD) equiparato ad un Dottorato di Ricerca.
• Livello nella classificazione nazionale (se pertinente)	Dottorato di Ricerca
• Date (da – a)	1991
• Nome e tipo di istituto di istruzione o formazione	Laurea in Medicina e Chirurgia, 110/110 cum laude, Università degli Studi di Milano. Titolo della Tesi: "Il carcinoma epatocellulare: analisi di 286 casi consecutivi", relatore Prof. Paolo Bianchi, correlatore Prof. Dario Conte.
• Principali materie / abilità professionali oggetto dello studio	
• Qualifica conseguita	Laurea in Medicina e Chirurgia, 110/110 cum laude
• Livello nella classificazione nazionale (se pertinente)	

CAPACITÀ E COMPETENZE PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA	Italiano
ALTRE LINGUE	
• Capacità di lettura	**INGLESE: OTTIMO**
• Capacità di scrittura	**INGLESE: OTTIMO**
• Capacità di espressione orale	**INGLESE: OTTIMO**
CAPACITÀ E COMPETENZE RELAZIONALI *Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.*	BUONE
CAPACITÀ E COMPETENZE ORGANIZZATIVE *Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.*	OTTIME
CAPACITÀ E COMPETENZE TECNICHE *Con computer, attrezzature specifiche, macchinari, ecc.*	
CAPACITÀ E COMPETENZE ARTISTICHE *Musica, scrittura, disegno ecc.*	

ALTRE CAPACITÀ E COMPETENZE

Competenze non precedentemente indicate.

PATENTE O PATENTI

ULTERIORI INFORMAZIONI

RICONOSCIMENTI

1995 – 1997 Vincitore per due anni consecutivi della Bancroft Scholarship del Queensland Institute of Medical Research, Brisbane, Australia.

2003 Vincitore di un finanziamento per 1 anno dal Comitato Telethon Fondazione ONLUS per la "Human genetic Bank of patient affected by Parkinson disease and parkinsonism" (grant n. GTF03009).

2004 Vincitore di un finanziamento per 3 anni dal Comitato Telethon Fondazione ONLUS per la "Human genetic Bank of patient affected by Parkinson disease and parkinsonism" (grant n. GTF04007).

2007 Vincitore di un finanziamento per 5 anni dal Comitato Telethon Fondazione ONLUS per la "Human genetic Bank of patient affected by Parkinson disease and parkinsonism" all'interno del "Telethon Network of Genetic Biobanks" (grant n. GTB07001).

2010 Vincitore come co-investigator di un finanziamento per 3 anni dal Italian Telethon Foundation per il progetto intitolato "Peripheral blood gene expression profiling of LRRK2 and Parkin monogenic forms of Parkinson's disease for disease assessment" (GGP10224).

2010 Vincitore come co-investigator di un finanziamento per 1 anno dal Michael J Fox Foundation per il progetto intitolato "Susceptibility genes for antipsychotic-induced extrapyramidal symptoms as modifier genes in Parkinson's disease and L-dopa treatment response"

2011 Vincitore come Principal Investigator di un finanziamento di 2 anni dalla Fondazione Telethon per il progetto intitolato "Identification of Recessive Genes Causative for Parkinson's Disease using Exome Sequencing" (GGP11164).

2014 Vincitore come coordinatore del gruppo italiano di un finanziamento per 3 anni per il progetto europeo "COURAGE-PD", COmprehensive Unbiased Risk factor Assessement for Genetics and Environment in Parkinson Disease (esauriente e non-condizionata valutazione dei fattori di rischio genetici e ambientali nella Malattia di Parkinson) all'interno del call "European research projects for the identification of genetic, epigenetic and environmental risk and protective factors for Neurodegenerative Diseases" del "Joint Programme – Neurodegenerative Disease Research (JPND)".

2017 Vincitore della Abilitazione Scientifica Nazionale per professore associato di seconda fascia (bando D.D. 1532/2016) nel settore concorsuale 06/A1-GENETICA MEDICA, valido dal 31/03/2017 al 31/03/2023 (art. 16, comma 1, Legge 240/10) (http://abilitazione.miur.it/public/pubblicarisultati_2016.php).

ALLEGATI

Pubblicazioni

Al 06/11/2018 sono autore di 121 articoli scientifici indicizzati su PubMed (http://www.ncbi.nlm.nih.gov/pubmed).

H-Index al 06/11/2018: 37 (goggle-scholar)

Il sottoscritto è consapevole delle sanzioni penali previste in casi di dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi, come stabilito ai sensi dell'art. 76 del DPR 28.12.2000 n. 445. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Decreto Legislativo 196/03.

Città , data

NOME E COGNOME (FIRMA)

Milano, 06/11/2018

Pubblicazioni

1) Falciani F, Terao M, **Goldwurm S**, Ronchi A, Gatti A, Minoia C, Li Calzi M, Cazzaniga G and Garattini E. (1994) Molibdenum (VI) salts convert the xanthine oxidoreductase apoprotein into the active enzyme in mouse L929 fibroblastic cells. *Biochemical Journal* 298:69-77.

2) Jazwinska EC, Pyper WR, Burt MJ, Francis JL, **Goldwurm S**, Webb SI, Lee SC, Halliday JW, Powell LW. (1995). Haplotype analysis in Australian haemochromatosis patients: evidence for a predominant ancestral haplotype exclusively associated with haemochromatosis. *Am J Hum Genet* 56(2): 428-433.

3) **Goldwurm S**, Menzies ML, Banyer JL, Powell LW, Jazwinska EC. (1997) Identification of a novel Krueppel-related zinc finger gene (ZNF184) mapping to 6p21.3. *Genomics* 40(3): 486-489.

4) **Goldwurm S** and Powell LW. (1997) Haemochromatosis after the discovery of HFE ("HLA-H"). *Gut*, 41(6), 855-856.

5) Jazwinska EC, Cullen LC, Zournazi A, Burt MJ, Van Der Griend B, **Goldwurm S**, and Little PRF. (1997) Isolation and characterisation of cosmids to intervals within a 4.5Mb region at 6p21.3. *DNA Sequence* 8(3) 147-150.

6) Banyer JL, **Goldwurm S**, Cullen LC, Van der Griend BFH, Smit DJ, Powell LW and Jazwinska EC. (1998) The Spinal Muscular Atrophy gene region at 5q13.1 has a paralogous chromosomal region at 6p21.3. *Mammalian Genome*, 9(3): 235-239.

7) George DK*, **Goldwurm S***, Macdonald GA, Cowley LC, Walker NI, Ward PJ, Jazwinska EC, and Powell LW. (1998) Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. *Gastroenterology*, 114(2): 311-318. * These authors contributed equally to this work.

8) **Goldwurm S**, Van der Griend BFH, Banyer JL, Cullen LC, Zournazi A, Menzies ML, Busfield F, Little PRF, Powell LW and Jazwinska EC. (1998) Generation of a transcription map distal to HLA-F. *Eur J Hum Genet*, 6(5): 475-486.

9) **Goldwurm S**, Casati C, Venturi N, Strada S, Santambrogio P, Indraccolo S, Arosio P, Cazzola M, Piperno A, Masera G and Biondi A. (2000) Biochemical and genetic defects underlying human congenital hypotransferrinemia. *The Hematology Journal* 1: 390-398.

10) **Goldwurm S** and Biondi A. (2000) Case of congenital hypotransferrinemia suggests that tissue hypoxia during fetal development may cause hypospadias. *Am J Med Genet* 95: 287-289.

11) **Goldwurm S** and Biondi A. (2000) Response to the letter to the editor by Fung. *Am J Med Genet* 95: 289-290.

12) Lalatta F and **Goldwurm S** (2000) Relevance of genetic counselling in genetic testing. *Minerva Biotech* 12: 15-24.

13) Venturi N., Rovelli A., Parini R., Menni F., Brambillasca F., Bertagnolio B., Uziel G., Gatti R., Filocamo M., Donati M.A., Biondi A., **Goldwurm S**. (2002) Molecular analysis of 30 mucopolysaccharidosis type I patients: evaluation of the mutational spectrum in Italian population and identification of 13 novel mutations. *Human Mutation*, 20: 231.

14) **Goldwurm S.** Genetic and molecular mechanisms of Parkinson disease. *Homeostasis*, 42, 2003, n.6: 267-268.

15) A.M. Bertoli-Avella, J.L. Giroud-Benitez, A. Akyol, E. Barbosa, O. Schaap, H.C. van der Linde, E. Martignoni, L. Lopiano, P. Lamberti, E. Fincati, A. Antonini, F. Stocchi, P. Montagna, F. Squitieri, P. Marini, G. Abbruzzese, G. Fabbrini, R. Marconi, A. Dalla Libera, G. Trianni, M. Guidi, A. De Gaetano, G. Boff Maegawa, A. De Leo, V. Gallai, G. de Rosa, N. Vanacore, G. Meco, C.M. van Duijn, B. A. Oostra, P. Heutink, V. Bonifati, MD, and The Italian Parkinson Genetics Network. Novel *parkin* mutations detected in patients with early-onset Parkinson's disease. *Mov Disord*, 2005 Apr;20(4):424-31. [name in Appendix].

16) Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, **Goldwurm S**, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V; Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. *Lancet*. 2005 Jan 29;365(9457):412-5.

17) Ghezzi D, Marelli C, Achilli A, **Goldwurm S**, Pezzoli G, Barone P, Pellecchia MT, Stanzione P, Brusa L, Bentivoglio AR, Bonuccelli U, Petrozzi L, Abbruzzese G, Marchese R, Cortelli P, Grimaldi D, Martinelli P, Ferrarese C, Garavaglia B, Sangiorgi S, Carelli V, Torroni A, Albanese A, Zeviani M. Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. *Eur J Hum Genet*. 2005 Jun;13(6):748-52.

18) Bonifati V, Rohe CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, Tavella A, Marconi R, Nicholl DJ, Chien HF, Fincati E, Abbruzzese G, Marini P, De Gaetano A, Horstink MW, Maat-Kievit JA, Sampaio C, Antonini A, Stocchi F, Montagna P, Toni V, Guidi M, Dalla Libera A, Tinazzi M, De Pandis F, Fabbrini G, **Goldwurm S**, de Klein A, Barbosa E, Lopiano L, Martignoni E, Lamberti P, Vanacore N, Meco G, Oostra BA; Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. *Neurology*. 2005 Jul 12;65(1):87-95.

19) Antonini A, **Goldwurm S,** Benti R, Prokisch H, Ebhardt M, Cilia R, Zini M, Righini A, Cossu G, Pezzoli G. Clinical, genetic and imaging characterization of one patient with late-onset slowly progressive Pantothenate Kinase-Associated Neurodegeneration. *Mov Disord* 2006 Mar;21(3):417-8.

20) **Goldwurm S**, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla Libera A, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G, Bonifati V. The G6055A (G2019S) mutation in LRRK2 is frequent in both early- and late-onset

Parkinson's disease and originates from a common ancestor. *J. Med. Genet.*, 2005 Nov;42(11):e65.
21) Karamohamed S, Latourelle JC, Racette BA, Perlmutter JS, Wooten GF, Lew MF, Klein C, Shill H, Golbe LI, Mark MH, Guttman M, Nicholson G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Tobin J, Suchowersky O, Labelle N, Growdon JH, Singer C, Watts RL, **Goldwurm S**, Pezzoli G, Baker KB, Giroux ML, Pramstaller PP, Burn DJ, Chinnery PF, Sherman S, Vieregge P, Litvan I, Gusella JF, Myers RH, Parsian A. BDNF genetic variants are associated with onset-age of familial Parkinson's disease: GenePD study. *Neurology* 2005 Dec 13;65(11):1823-5.
22) Ceravolo R, Antonini A, Volterrani D, Rossi C, **Goldwurm S**, Di Maria E, Kiferle L, Bonuccelli U, Murri. Dopamine transporter imaging study in parkinsonism occurring in Fragile X Premutation carriers. *Neurology* 2005 Dec 27;65(12):1971-3.
23) Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, **Goldwurm S,** Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V; Italian Parkinson's Genetics Network. Comprehensive analysis of the *LRRK2* gene in sixty families with Parkinson's disease. *Eur J Hum Genet* 2006 Mar;14(3):322-31.
24) Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A, Guttman M, Nicholson G, Xu G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Suchowersky O, Labelle N, Growdon JH, Singer C, Watts RL, **Goldwurm S**, Pezzoli G, Baker KB, Pramstaller PP, Burn DJ, Chinnery PF, Sherman S, Vieregge P, Litvan I, Gillis T, MacDonald ME, Myers RH, Gusella JF. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. *Arch Neurol* 2006 Jun;63(6):826-32.
25) **Goldwurm S**, Zini M, Di Fonzo A, De Gaspari D, Siri C, Simons EJ, van Doeselaar M, Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani C, Meucci N, Sacilotto G, Cilia R, Isaias IU, Bonetti A, Sironi F, Ricca S, Oostra BA, Bonifati V, and Pezzoli G. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. *Parkinsonism Relat Disord*, 2006 Oct;12(7):410-9. Epub 2006 Jun 5.
26) Isaias IU, Benti R, **Goldwurm S**, Zini M, Cilia R, Gerundini P, Di Fonzo A, Bonifati V, Pezzoli G, Antonini A. Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. *Mov Disord*. 2006 Aug;21(8):1144-7
27) **Goldwurm S.** La Genetica della Malattia di Parkinson. *Journal of Neurodegenerative Disorders* Anno 2 • nr. 1 – Marzo-Aprile 2006
28) Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, Chartier-Harlin MC,Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert JC, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan EK, Van Broeckhoven C; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA. 2006 Aug 9;296(6):661-70. [name in appendix]
29) Elbaz A, Nelson LM, Payami H, Ioannidis JP, Fiske BK, Annesi G, Carmine Belin A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins DS, Kawakami H, Kruger R, Marder KS, Mayeux RP, Mellick GD, Nutt JG, Ritz B, Samii A, Tanner CM, Van Broeckhoven C, Van Den Eeden SK, Wirdefeldt K, Zabetian CP, Dehem M, Montimurro JS, Southwick A, Myers RM, Trikalinos TA. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol. 2006 Nov;5(11):917-23 [name in appendix]
30) Wilk JB, Tobin JE, Suchowersky O, Shill H, Klein C, Wooten GF, Lew M, Mark MH, Guttman M, Watts RL, Singer C, Growdon J, Latourelle JC, Saint-Hilaire M, DeStefano AL, Prakash R, Williamson S, Berg CJ, Sun M, **Goldwurm S**, Pezzoli G, Racette BA, Perlmutter JS, Parsian A, Baker K, Giroux ML, Litvan I, Pramstaller PP, Nicholson GA, Burn DJ, Chinnery, PF, Vieregge P, Slevin JT, Cambi F, MacDonald ME, Gusella JF, Myers RH, Golbe LI. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD Study. *Neurology*, 2006; 67:2206-2210.
31) Marongiu R, Brancati F, Antonini A, Ialongo T, Ceccarini C, Scarciolla O, Capalbo A, Benti R, Pezzoli G, Dallapiccola B, **Goldwurm S**, Valente EM. Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. *Hum Mutat*. 2007;28(1):98
32) **Goldwurm S**, Zini M, Mariani L, Tesei S, Miceli R, Sironi F, Clementi M, Bonifati V, Pezzoli G. Evaluation of *LRRK2* G2019S penetrance: relevance for genetic counselling in Parkinson's Disease. *Neurology*, 2007; 68: 1141-1143.
33) Grunewald A, Breedveld GJ, Lohmann-Hedrich K, Rohe CF, Konig IR, Hagenah J, Vanacore N, Meco G, Antonini A, **Goldwurm S**, Lesage S, Durr A, Binkofski F, Siebner H, Munchau A, Brice A, Oostra BA, Klein C, Bonifati V. Biological effects of the PINK1 c.1366C>T mutation: Implications in Parkinson disease pathogenesis. Neurogenetics. 2007 Apr;8(2):103-9.
34) Kraff J, Tang HT, Cilia R, Canesi M, Pezzoli G, **Goldwurm S**, Hagerman PJ, Tassone F. Screen for excess *FMR1* premutation alleles among males with parkinsonism. *Arch Neurol* 2007 Jul;64(7):1002-6.

35) Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, Fabbrini G, Marconi R, Fincati E, Abbruzzese G, Marini P, Squitieri F, Horstink MW, Montagna P, Libera AD, Stocchi F, **Goldwurm S**, Ferreira JJ, Meco G, Martignoni E, Lopiano L, Jardim LB, Oostra BA, Barbosa ER; The Italian Parkinson Genetics Network, Bonifati V. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson's disease. *Neurology* 2007 May 8;68(19):1557-62.

36) Foglieni B, Ferrari F, **Goldwurm S**, Santambrogio P, Castiglioni E, Sessa M, Antonietta Volontè M, Lalli S, Galli C, Wang XS, Connor J, Sironi F, Canesi M, Biasiotto G, Pezzoli G, Levi S, Ferrari M, Arosio P, Cremonesi L. Analysis of ferritin genes in Parkinson disease. Clin Chem Lab Med 2007;45(11):1450–1456

37) Sironi F, Primignani P, Zini M, Tunesi S, Ruffmann C, Ricca S, Brambilla T, Antonini A, Tesei S, Canesi M, Zecchinelli A, Mariani C, Meucci N, Sacilotto G, Cilia R, Isaias IU, Garavaglia B, Ghezzi D, Travi M, Decarli A, Coviello DA, Pezzoli G, **Goldwurm S**. Parkin analysis in early onset Parkinson's disease. Parkinsonism Relat Disord. 2008 May;14(4):326-333. Epub 2007 Nov 19.

38) Marongiu R, Ferraris A, Ialongo T, Michiorri S, Soleti F, Ferrari F, Elia AE, Ghezzi D, Albanese A, Altavista MC, Antonini A, Barone P, Brusa L, Cortelli P, Martinelli P, Pellecchia MT, Pezzoli G, Scaglione C, Stanzione P, Tinazzi M, Zecchinelli A, Zeviani M, Cassetta E, Garavaglia B, Dallapiccola B, Bentivoglio AR, Valente EM; Italian PD Study Group. PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum Mutat. 2008 Apr;29(4):565. [name in appendix]

39) Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, **Goldwurm S**, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008 Apr 15;70(16 Pt 2):1456-60. Epub 2008 Mar 12.

40) Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, Golbe LI, Mark MH, Growdon JH, Wooten GF, Racette BA, Perlmutter JS, Watts R, Guttman M, Baker KB, **Goldwurm S**, Pezzoli G, Singer C, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Laramie JM, Destefano AL, Litvan I, Nicholson G, Corbett A, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Sherman S, Al-Hinti J, Drasby E, Nance M, Moller AT, Ostergaard K, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. Haplotypes and gene expression implicate the MAPT region for Parkinson disease. The GenePD Study. Neurology. Neurology. 2008 Jul 1;71(1):28-34.

41) Biasiotto G, **Goldwurm S**, Finazzi D, Tunesi S, Zecchinelli A, Sironi F, Pezzoli G, Arosio P. HFE gene mutations in a population of Italian Parkinson's disease patients. *Parkinsonism Relat Disord*, 2008;14(5):426-30.

42) Lautier C, **Goldwurm S**, Dürr A, Giovannone B, Tsiaras WG, Pezzoli G, Brice A, Smith RJ. Mutations in the *GIGYF2* Gene at the PARK11 Locus in Familial Parkinson's Disease. *Am J Hum Gen*, 2008, Apr 11;82(4):822-833. Epub 2008 Mar 20.

43) Panzacchi A, Moresco RM, Garibotto V, Antonini A, Gobbo C, Isaias IU, **Goldwurm S**, Bonaldi L, Carpinelli A, Pezzoli G, Fazio F, Perani D. A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset. Neurobiol Dis. 2008 Jul;31(1):102-9. Epub 2008 Apr 20.

44) Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, **Goldwurm S**, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; on behalf of the International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008 Jul;7(7):583-90. Epub 2008 Jun 6.

45) DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts R, Guttman M, Racette BA, Perlmutter JS, Marlor L, Shill HA, Singer C, **Goldwurm S**, Pezzoli G, Saint-Hilaire MH, Hendricks AE, Gower A, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet. 2008 Aug;124(1):95-9. Epub 2008 Jun 29.

46) McNicoll CF, Latourelle JC, MacDonald PhD ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Saint-Hilaire MH, Massood T, Huskey KW, DeStefano AL, Gillis T, Mysore J, **Goldwurm S**, Pezzoli G, Baker K, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD Study. *Movement Disorders*, Mov Disord. 2008 Aug 15;23(11):1596-601.

47) Pankratz N, Wilk JB, Latourelle JC, Destefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH; The PSG—PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009 Jan;124(6):593-605. Epub 2008 Nov 6. (name in the appendix)

48) Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, **Goldwurm S**, Pezzoli G, Zini M,

Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, Destefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's Disease: the GenePD study. BMC Med. 2008 Nov 5;6(1):32.

49) Cilia R, Kraff J, Canesi M, Pezzoli G, **Goldwurm S**, Amiri K, Tang HT, Pan R, Hagerman PJ, Tassone F. Screening for the presence of FMR1 Premutation Alleles in Females with Parkinsonism. Arch Neurol. 2009 Feb;66(2):244-9.

50) Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wüllner U, **Goldwurm S**, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol. 2009 May;65(5):610-4.

51) Giovannone B, Tsiaras WG, De la Monte S, Klysik J, Lautier C, Karashchuk G, **Goldwurm S**, Smith RJ. *GIGYF2* Gene Disruption in Mice Results in Neurodegeneration and Altered Insulin-like Growth Factor Signaling. Hum Mol Genet. 2009 Dec 1;18(23):4629-39. Epub 2009 Sep 10.

52) Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, **Goldwurm S**, Pezzoli G, Mariani CB, Destefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Foroud T, Coordinators PP, Laboratory PP, Coordinators GI, Laboratories GM. Genomewide Association Study for Onset Age in Parkinson Disease. BMC Med Genet. 2009 Sep 22;10(1):98. [Epub ahead of print]

53) Siri C, Cilia R, De Gaspari D, Villa F, **Goldwurm S,** Marco C, Pezzoli G, Antonini A. Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. Neurol Sci. 2009 Oct 6. [Epub ahead of print]

54) Elstner M, Morris CM, Heim K, Lichtner P, Bender A, Mehta D, Schulte C, Sharma M, Hudson G, **Goldwurm S**, Giovanetti A, Zeviani M, Burn DJ, McKeith IG, Perry RH, Jaros E, Krüger R, Wichmann HE, Schreiber S, Campbell H, Wilson JF, Wright AF, Dunlop M, Pistis G, Toniolo D, Chinnery PF, Gasser T, Klopstock T, Meitinger T, Prokisch H, Turnbull DM. Single cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol. 2009 Dec;66(6):792-8.

55) Sironi F, Trotta L, Antonini A, Zini M, Ciccone R, Della Mina E, Meucci N, Sacilotto G, Primignani P, Brambilla T, Coviello DA, Pezzoli G, **Goldwurm S**. alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. Parkinsonism Relat Disord. 2010 Mar;16(3):228-31.

56) Guella I, Pistocchi A, Asselta R, Rimoldi V, Ghilardi A, Sironin F, Trotta L, Primignani P, Zini M, Zecchinelli A, Coviello D, Pezzoli G, Del GiaccoL, Duga S, **Goldwurm S**. Mutational screening and zebrafish functional analysis of GIGYF2 as a Parkinson-disease gene. Neurobiol Aging. 2011 Nov;32(11):1994-2005. Epub 2010 Jan 8.

57) Sironi F, Primignani P, **Goldwurm S**. Comment on "Compound heterozygosity in DJ-1 gene non-coding portion related to Parkinsonism". Parkinsonism Relat Disord. 2010 Jun;16(5):360-1;

58) Borroni B, Del Bo R, **Goldwurm S**, Archetti S, Bonvicini C, Agosti C, Bigni B, Papetti A, Ghezzi S, Sacilotto G, Pezzoli G, Gennarelli M, Bresolin N, Comi GP, Padovani A. VEGF Haplotypes are Associated with Increased Risk to Progressive Supranuclear Palsy and Corticobasal Syndrome. J Alzheimers Dis. 2010;21(1):87-94.

59) Borroni B, **Goldwurm S**, Cerini C, Cosseddu M, Meucci N, Mariani C, Pezzoli G, Padovani A Familial aggregation in Progressive Supranuclear Palsy and Corticobasal Syndrome. Eur J Neurol. 2010 May 11. [Epub ahead of print]

60) Castiglioni E, Finazzi D, **Goldwurm S**, Levi S, Pezzoli G, Garavaglia B, Nardocci N, Malcovati L, Porta MG, Galli A, Forni GL, Girelli D, Maccarinelli F, Poli M, Ferrari M, Cremonesi L, Arosio P. Sequence Variations in Mitochondrial Ferritin: Distribution in Healthy Controls and Different Types of Patients. Genet Test Mol Biomarkers. 2010 Oct 12. [Epub ahead of print]

61) Castiglioni E, Finazzi D, **Goldwurm S**, Pezzoli G, Forni G, Girelli D, Maccarinelli F, Poli M, Ferrari M, Cremonesi L, Arosio P. Analysis of Nucleotide Variations in Genes of Iron Management in Patients of Parkinson's Disease and Other Movement Disorders. Parkinsons Dis. 2010 Oct 17;2011:827693. doi:10.4061/2011/827693.

62) Dimitriu A, Pacheco CD, Wilk JB, Strathearn KE, Latourelle JC, **Goldwurm S**, Pezzoli G, Rochet JC, Lindquist S, Myers RH. Cyclin-G associated Kinase Modifies {alpha}-Synuclein Expression Levels and Toxicity in Parkinson's disease: Results from the GenePD Study. Hum Mol Genet. 2011 Apr 15;20(8):1478-87. Epub 2011 Jan 21.

63) **Goldwurm S**, Tunesi S, Tesei S, Zini M, Sironi F, Primignani P, Magnani C, Pezzoli G. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease. Mov Disord. 2011 Sep;26(11):2144-5. doi: 10.1002/mds.23807. Epub 2011 Jun 28.

64) Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, **Goldwurm S**, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011 Jun 19;43(7):699-705. doi: 10.1038/ng.859.

65) Brighina L, Riva C, Bertola F, Fermi S, Saracchi E, Piolti R, **Goldwurm S**, Pezzoli G, Ferrarese C. Association analysis of *PARP1* polymorphisms with Parkinson's disease. Parkinsonism Relat Disord. 2011 Nov;17(9):701-4. Epub 2011 Jul 20.
66) Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL; PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Copy number variation in familial Parkinson disease. PLoS One. 2011;6(8):e20988. Epub 2011 Aug 2. (name in appendix)
67) Cilia R, Sironi F, Akpalu A, Cham M, Sarfo FS, Brambilla T, Bonetti A, Amboni M, **Goldwurm S**, Pezzoli G. Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana. J Neurol. 2012 Mar;259(3):569-70. Epub 2011 Aug 14.
68) Ruffmann C, Giaccone G, Canesi M, Bramerio M, **Goldwurm S**, Gambacorta M, Rossi G, Tagliavini F, Pezzoli G. Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremor-dominant parkinsonism. Neuropathol Appl Neurobiol. 2012 Jun;38(4):382-6. doi: 10.1111/j.1365-2990.2011.01216.x.
69) Trotta L, Guella I, Soldà G, Sironi F, Tesei S, Canesi M, Pezzoli G, **Goldwurm S**, Duga S, Asselta R. SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat Disord. Parkinsonism Relat Disord. 2012 Mar;18(3):257-62. Epub 2011 Nov 21.
70) van Es MA, Schelhaas HJ, van Vught PW, Ticozzi N, Andersen PM, Groen EJ, Schulte C, Blauw HM, Koppers M, Diekstra FP, Fumoto K, LeClerc AL, Keagle P, Bloem BR, Scheffer H, van Nuenen BF, van Blitterswijk M, van Rheenen W, Wills AM, Lowe PP, Hu GF, Yu W, Kishikawa H, Wu D, Folkerth RD, Mariani C, **Goldwurm S**, Pezzoli G, Van Damme P, Lemmens R, Dahlberg C, Birve A, Fernández-Santiago R, Waibel S, Klein C, Weber M, van der Kooi AJ, de Visser M, Verbaan D, van Hilten JJ, Heutink P, Hennekam EA, Cuppen E, Berg D, Brown RH Jr, Silani V, Gasser T, Ludolph AC, Robberecht W, Ophoff RA, Veldink JH, Pasterkamp RJ, de Bakker PI, Landers JE, van de Warrenburg BP, van den Berg LH. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol. 2011 Dec;70(6):964-73. doi: 10.1002/ana.22611.
71) Guella I, Soldà G, Cilia R, Pezzoli G, Asselta R, Duga S, **Goldwurm S**. The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. Mov Disord. 2012 May;27(6):800-1. doi: 10.1002/mds.24927. Epub 2012 Jan 25.
72) Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012 Mar;71(3):370-84. doi: 10.1002/ana.22687. (name in appendix).
73) Ruffmann C, Zini M, **Goldwurm S**, Bramerio M, Spinello S, Rusconi D, Gambacorta M, Tagliavini F, Pezzoli G, Giaccone G. Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2). Acta Neuropathol. 2012 Jun;123(6):901-3. Epub 2012 May 4.
74) Cartelli D, **Goldwurm S**, Casagrande F, Pezzoli G, Cappelletti G. Microtubule destabilization is shared by genetic and idiopathic Parkinson's disease patient fibroblasts. PLoS One. 2012;7(5):e37467. Epub 2012 May 22.
75) Greenbaum L, Rigbi A, Lipshtat N, Cilia R, Tesei S, Asselta R, Djaldetti R, **Goldwurm S** and Lerer B. Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: Gene and smoking status interaction. Parkinsonism Relat Disord., 2013 Jan;19(1):72-6. doi: 10.1016/j.parkreldis.2012.07.007. Epub 2012 Aug 9..
76) Brighina L, Riva C, Bertola F, Saracchi E, Fermi S, **Goldwurm S**, Ferrarese C. Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease. Neurobiol Aging. 2013 Jun;34(6):1712.e9-13. doi: 10.1016/j.neurobiolaging.2012.12.020. Epub 2013 Jan 28.
77) Srulijes K, Hauser AK, Guella I, Asselta R, Brockmann K, Schulte C, Soldà G, Cilia R, Maetzler W, Schols L, Wenning GK, Poewe W, Barone P, Wüllner U, Oertel W, Berg D, **Goldwurm S,** Gasser T. No association of GBA mutations and multiple system atrophy. Eur J Neurol. 2013 Apr;20(4):e61-2. doi: 10.1111/ene.12086. No abstract available.
78) Greenbaum L, **Goldwurm S**, Zozulinsky P, Lifschytz T, Cohen OS, Yahalom G, Cilia R, Tesei S, Asselta R, Inzelberg R, Kohn Y, Hassin-Baer S, Lerer B. Do Tardive Dyskinesia and L-Dopa Induced Dyskinesia Share Common Genetic Risk Factors? An Exploratory Study. J Mol Neurosci. 2013 May 12. [Epub ahead of print]
79) Heckman MG, Elbaz A, Soto-Ortolaza AI, Serie DJ, Aasly JO, Annesi G, Auburger G, Bacon JA, Boczarska-Jedynak M, Bozi M, Brighina L, Chartier-Harlin MC, Dardiotis E, Destée A, Ferrarese C, Ferraris A, Fiske B, Gispert S, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lin CH, Lohmann K, Loriot MA, Lynch T, Mellick GD, Mutez E, Opala G, Park SS, Petrucci S, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Tomiyama H, Uitti RJ, Valente EM, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Xiromerisiou G, Maraganore DM, Farrer MJ, Ross OA; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiol Aging. 2014 Jan;35(1):266.e5-14. doi: 10.1016/j.neurobiolaging.2013.07.013. Epub 2013 Aug 17. (name in appendix)

80) Filocamo M, Baldo C, **Goldwurm S**, Renieri A, Angelini C, Moggio M, Mora M, Merla G, Politano L, Garavaglia B, Casareto L, Bricarelli FD. Telethon Network of Genetic Biobanks: a key service for diagnosis and research on rare diseases. Orphanet J Rare Dis. 2013 Aug 30;8(1):129. [Epub ahead of print]

81) Ticozzi N, Tiloca C, Calini D, Gagliardi S, Altieri A, Colombrita C, Cereda C, Ratti A, Pezzoli G, Borroni B, **Goldwurm S**, Padovani A, Silani V. C9orf72 repeat expansions are restricted to the ALS-FTD spectrum. Neurobiol Aging. 2014 Apr;35(4):936.e13-7. doi: 10.1016/j.neurobiolaging.2013.09.037. Epub 2013 Oct 2.

82) Sironi F, Primignani P, Ricca S, Tunesi S, Zini M, Tesei S, Cilia R, Pezzoli G, Seia M**, Goldwurm S**. DJ.1 analysis in a large cohort of Italian early onset Parkinson Disease. Neurosci Lett. 2013 Dec 17;557 Pt B:165-70. doi: 10.1016/j.neulet.2013.10.048.

83) Chung SJ, Biernacka JM, Armasu SM, Anderson K, Frigerio R, Aasly JO, Annesi G, Bentivoglio AR, Brighina L, Chartier-Harlin MC, **Goldwurm S**, Hadjigeorgiou G, Jasinska-Myga B, Jeon BS, Kim YJ, Krüger R, Lesage S, Markopoulou K, Mellick G, Morrison KE, Puschmann A, Tan EK, Crosiers D, Theuns J, Van Broeckhoven C, Wirdefeldt K, Wszolek ZK, Elbaz A, Maraganore DM; on behalf of the Genetic Epidemiology of Parkinson's Disease Consortium. Alpha-synuclein repeat variants and survival in Parkinson's disease. Mov Disord. 2014 Feb 27. doi: 10.1002/mds.25841. [Epub ahead of print]

84) Cilia R, Siri C, Rusconi D, Allegra R, Ghiglietti A, Sacilotto G, Zini M, Zecchinelli AL, Asselta R, Duga S, Paganoni AM, Pezzoli G, Seia M, **Goldwurm S**. LRRK2 mutations in Parkinson's disease: Confirmation of a gender effect in the Italian population. Parkinsonism Relat Disord. 2014 Aug;20(8):911-4. doi: 10.1016/j.parkreldis.2014.04.016. Epub 2014 Apr 25.

85) Sharma M, Wenning G, Krüger R; European Multiple-System Atrophy Study Group (EMSA-SG). Mutant COQ2 in multiple-system atrophy. N Engl J Med. 2014 Jul 3;371(1):80-1. doi: 10.1056/NEJMc1311763#SA2. Name in appendix.

86) Allegra R, Tunesi S, Cilia R, Pezzoli G, **Goldwurm S**. LRRK2-G2019S mutation is not associated with an increased cancer risk: A kin-cohort study. Mov Disord. 2014 Sep;29(10):1325-6. doi: 10.1002/mds.25969. Epub 2014 Jul 22.

87) Cilia R, Reale C, Castagna A, Nasca A, Muzi-Falconi M, Barzaghi C, Marzegan A, Granata M, Marotta G, Sacilotto G, Vallauri D, Pezzoli G, **Goldwurm S**, Garavaglia B. Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia. Neurology. 2014 83:1155-1162; published ahead of print August 22, 2014.

88) Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014 Sep;46(9):989-93. doi: 10.1038/ng.3043. Epub 2014 Jul 27. Name listed as “collaborator” in appendix.

89) Pezzoli G, Klersy C, Cilia R, Canesi M, Zecchinelli AL, Mariani CB, Tesei S, Sacilotto G, Meucci N, Zini M, Isaias IU, Ruffmann C, Barichella M, Cassani E, **Goldwurm S**, Cereda E. Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic. Parkinsonism Relat Disord. 2014 Nov;20(11):1181-5. doi: 10.1016/j.parkreldis.2014.08.017.

90) Asselta R, Rimoldi V, Siri C, Cilia R, Guella I, Tesei S, Soldà G, Pezzoli G, Duga S, **Goldwurm S**. Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism Relat Disord. 2014 Nov;20(11):1215-20. doi: 10.1016/j.parkreldis.2014.09.003. Epub 2014 Sep 9.

91) Cilia R, Cereda E, Klersy C, Canesi M, Zecchinelli AL, Mariani CB, Tesei S, Sacilotto G, Meucci N, Zini M, Ruffmann C, Isaias IU, **Goldwurm S**, Pezzoli G. Parkinson's disease beyond 20 years. J Neurol Neurosurg Psychiatry. 2014 Oct 3. pii: jnnp-2014-308786. doi: 10.1136/jnnp-2014-308786. [Epub ahead of print]

92) Quadri M, Yang X, Cossu G, Olgiati S, Saddi VM, Breedveld GJ, Ouyang L, Hu J, Xu N, Graafland J, Ricchi V, Murgia D, Guedes LC, Mariani C, Marti MJ, Tarantino P, Asselta R, Valldeoriola F, Gagliardi M, Pezzoli G, Ezquerra M, Quattrone A, Ferreira J, Annesi G, **Goldwurm S**, Tolosa E, Oostra BA, Melis M, Wang J, Bonifati V. An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate. Neurogenetics. 2015 Jan;16(1):55-64. doi: 10.1007/s10048-014-0425-x. Epub 2014 Oct 8.

93) Theuns J, Verstraeten A, Sleegers K, Wauters E, Gijselinck I, Smolders S, Crosiers D, Corsmit E, Elinck E, Sharma M, Krüger R, Lesage S, Brice A, Chung SJ, Kim MJ, Kim YJ, Ross OA, Wszolek ZK, Rogaeva E, Xi Z, Lang AE, Klein C, Weissbach A, Mellick GD, Silburn PA, Hadjigeorgiou GM, Dardiotis E, Hattori N, Ogaki K, Tan EK, Zhao Y, Aasly J, Valente EM, Petrucci S, Annesi G, Quattrone A, Ferrarese C, Brighina L, Deutschländer A, Puschmann A, Nilsson C, Garraux G, LeDoux MS, Pfeiffer RF, Boczarska-Jedynak M, Opala G, Maraganore

DM, Engelborghs S, De Deyn PP, Cras P, Cruts M, Van Broeckhoven C; GEO-PD Consortium. Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease. Neurology. 2014 Nov 18;83(21):1906-13. doi: 10.1212/WNL.0000000000001012. Epub 2014 Oct 17. (name listed in Collaborators).

94) Cereda E, Cilia R, Klersy C, Canesi M, Zecchinelli AL, Mariani CB, Tesei S, Sacilotto G, Meucci N, Zini M, Isaias IU, Cassani E, **Goldwurm S**, Barichella M, Pezzoli G. Swallowing disturbances in Parkinson's disease: A multivariate analysis of contributing factors. Parkinsonism Relat Disord. 2014 Oct 6;20(12):1382-1387. doi: 10.1016/j.parkreldis.2014.09.031.

95) Mora M, Angelini C, Bignami F, Bodin A, Crimi M, Di Donato J, Felice A, Jaeger C, Karcagi V, LeCam Y, Lynn S, Meznaric M, Moggio M, Monaco L, Politano L, de la Paz MP, Saker S, Schneiderat P, Ensini M, Garavaglia B, Gurwitz D, Johnson D, Muntoni F, Puymirat J, Reza M, Voit T, Baldo C, Bricarelli FD, **Goldwurm S**, Merla G, Pegoraro E, Renieri A, Zatloukal K, Filocamo M, Lochmüller H. The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. Eur J Hum Genet. 2014 Dec 24. doi: 10.1038/ejhg.2014.272.

96) Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, **Goldwurm S**, Frisén J, Deierborg T, Roybon L. Alpha-Synuclein Expression in the Oligodendrocyte Lineage: an In Vitro and In Vivo Study Using Rodent and Human Models. Stem Cell Reports. 2015 Aug 11;5(2):174-84. doi: 10.1016/j.stemcr.2015.07.002. Epub 2015 Jul 30.

97) Wang L, Aasly JO, Annesi G, Bardien S, Bozi M, Brice A, Carr J, Chung SJ, Clarke C, Crosiers D, Deutschländer A, Eckstein G, Farrer MJ, **Goldwurm S**, Garraux G, Hadjigeorgiou GM, Hicks AA, Hattori N, Klein C, Jeon B, Kim YJ, Lesage S, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pihlstrøm L, Pramstaller PP, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Silburn PA, Theuns J, Tan EK, Tomiyama H, Toft M, Van Broeckhoven C, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore DM, Krüger R, Sharma M; GEO-PD Consortium. Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology October 13, 2015 85:1283-1292.

98) Cereda E, Cilia R, Klersy C, Siri C, Pozzi B, Reali E, Colombo A, Zecchinelli AL, Mariani CB, Tesei S, Canesi M, Sacilotto G, Meucci N, Zini M, Isaias IU, Barichella M, Cassani E, **Goldwurm S**, Pezzoli G. Dementia in Parkinson's disease: Is male gender a risk factor? Parkinsonism Relat Disord. 2016 Mar 2. pii: S1353-8020(16)30052-9. doi: 10.1016/j.parkreldis.2016.02.024.

99) Staffan Holmqvist, Šárka Lehtonen, Margarita Chumarina, Katja A Puttonen, Carla Azevedo, Olga Lebedeva, Marika Ruponen, Minna Oksanen, Mehdi Djelloul, Anna Collin, Stefano Goldwurm, Morten Meyer, Maria Lagarkova, Sergei Kiselev, Jari Koistinaho & Laurent Roybon. Creation of a library of induced pluripotent stem cells from Parkinsonian patients. npj Parkinson's Disease (2016) 2, 16009; doi:10.1038/npjparkd.2016.9; published online 26 May 2016 (this journal is not indexed in PubMed. https://www.nature.com/articles/npjparkd20169)

100) Cilia R, Benfante R, Asselta R, Marabini L, Cereda E, Siri C, Pezzoli G, Goldwurm S*, Fornasari D*. Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease. Parkinsonism Relat Disord. 2016 Aug;29:96-103. doi: 10.1016/j.parkreldis.2016.05.017. *These authors shared senior authorship. (IF 4.484)

101) Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K, Mencacci NE, Schottlaender L, Chelban V, Ling H, O'Sullivan SS, Wood NW, Traynor BJ, Ferrucci L, Federoff HJ, Mhyre TR, Morris HR, Deuschl G, Quinn N, Widner H, Albanese A, Infante J, Bhatia KP, Poewe W, Oertel W, Höglinger GU, Wüllner U, Goldwurm S, Pellecchia MT, Ferreira J, Tolosa E, Bloem BR, Rascol O, Meissner WG, Hardy JA, Revesz T, Holton JL, Gasser T, Wenning GK, Singleton AB, Houlden H; European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group. A genome-wide association study in multiple system atrophy. Neurology. 2016 Oct 11;87(15):1591-1598. doi 10.1212/WNL.0000000000003221 (IF 7.592)

102) Cilia R, Tunesi S, Marotta G, Cereda E, Siri PsyD C, Tesei S, Zecchinelli A, Canesi M, Mariani CB, Meucci N, Sacilotto G, Zini M, Barichella M, Magnani C, Duga S, Asselta R, Soldà G, Seresini A, Seia M, Pezzoli G, Goldwurm S. Survival and dementia in GBA-associated Parkinson Disease: The mutation matters. Ann Neurol. 2016 Nov;80(5):662-673. doi: 10.1002/ana.24777. (IF 9.890)

103) Baldo C, Casareto L, Renieri A, Merla G, Garavaglia B, Goldwurm S, Pegoraro E, Moggio M, Mora M, Politano L, Sangiorgi L, Mazzotti R, Viotti V, Meloni I, Pellico MT, Barzaghi C, Wang CM, Monaco L, Filocamo M. The alliance between genetic biobanks and patient organisations: the experience of the telethon network of genetic biobanks. Orphanet J Rare Dis. 2016 Oct 24;11(1):142. (IF 3.507)

104) Cassani E, Barichella M, Ferri V, Pusani C, Goldwurm S, Siri C, Zini M, Zorzi GS, Cereda E, Iorio L, Pinelli G, Sacilotto G, Pezzoli G. Protein-redistribution diet in a case of tyrosine hydroxylase enzyme deficiency. Mov Disord. 2017 May;32(5):794-795. doi: 10.1002/mds.26963.

105) Lee AJ, Wang Y, Alcalay RN, Mejia-Santana H, Saunders-Pullman R, Bressman S, Corvol JC, Brice A, Lesage S, Mangone G, Tolosa E, Pont-Sunyer C, Vilas D, Schüle B, Kausar F, Foroud T, Berg D, Brockmann K, Goldwurm S, Siri C, Asselta R, Ruiz-Martinez J, Mondragón E, Marras C, Ghate T, Giladi N, Mirelman A, Marder K; Michael J. Fox LRRK2 Cohort Consortium. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. Mov Disord. 2017 Jun 22. doi: 10.1002/mds.27059. [Epub ahead of print]

106) Holmqvist S, Lehtonen Š, Chumarina M, Puttonen KA, Azevedo C, Lebedeva O, Ruponen M, Oksanen M, Djelloul M, Collin A, Goldwurm S, Meyer M, Lagarkova M, Kiselev S, Koistinaho J, Roybon L. Creation of a library of induced pluripotent stem cells from Parkinsonian patients. NPJ Parkinsons Dis. 2016 Jun 2;2:16009. doi: 10.1038/npjparkd.2016.9. eCollection 2016. PMID: 28725696

107) Cilia R, Asselta R, Cereda E, Benfante R, Barbella G, Vallauri D, Marabini L, Fornasari D, Goldwurm S, Pezzoli G. Opioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):323-324. doi: 10.1136/jnnp-2017-316235. Epub 2017 Jul 19. PMID: 28724719

108) Straniero L, Guella I, Cilia R, Parkkinen L, Rimoldi V, Young A, Asselta R, Soldà G, Sossi V, Stoessl AJ, Priori A, Nishioka K, Hattori N, Follett J, Rajput A, Blau N, Pezzoli G, Farrer MJ, Goldwurm S, Rajput AH, Duga S. DNAJC12 and dopa-responsive nonprogressive parkinsonism. Ann Neurol. 2017 Oct;82(4):640-646. doi: 10.1002/ana.25048. Epub 2017 Oct 11.

109) Straniero L, Rimoldi V, Samarani M, Goldwurm S, Di Fonzo A, Krüger R, Deleidi M, Aureli M, Soldà G, Duga S, Asselta R. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Sci Rep. 2017 Oct 5;7(1):12702. doi: 10.1038/s41598-017-12973-5.

110) Cartelli D, Amadeo A, Calogero AM, Casagrande FVM, De Gregorio C, Gioria M, Kuzumaki N, Costa I, Sassone J, Ciammola A, Hattori N, Okano H, Goldwurm S, Roybon L, Pezzoli G, Cappelletti G. Parkin absence accelerates microtubule aging in dopaminergic neurons. Neurobiol Aging. 2018 Jan;61:66-74. doi: 10.1016/j.neurobiolaging.2017.09.010. Epub 2017 Sep 20. PMID: 29040870

111) Russ K, Marote A, Savchenko E, Collin A, Goldwurm S, Pomeshchik Y, Roybon L. Generation of a human induced pluripotent stem cell line (CSC-40) from a Parkinson's disease patient with a PINK1 p.Q456X mutation. Stem Cell Res. 2018 Mar;27:61-64. doi: 10.1016/j.scr.2018.01.001. Epub 2018 Jan 4. PMID: 29331938

112) Savchenko E, Marote A, Russ K, Collin A, Goldwurm S, Roybon L, Pomeshchik Y. Generation of a human induced pluripotent stem cell line (CSC-42) from a patient with sporadic form of Parkinson's disease. Stem Cell Res. 2018 Mar;27:78-81. doi: 10.1016/j.scr.2018.01.002. Epub 2018 Jan 4. PMID: 29334629

113) Marote A, Pomeshchik Y, Goldwurm S, Collin A, Lamas NJ, Pinto L, Salgado AJ, Roybon L. Generation of an integration-free induced pluripotent stem cell line (CSC-43J) from a patient with sporadic Parkinson's disease. Stem Cell Res. 2018 Mar;27:82-85. doi: 10.1016/j.scr.2018.01.007. Epub 2018 Jan 4. PMID: 29334630

114) Marote A, Pomeshchik Y, Goldwurm S, Collin A, Lamas NJ, Pinto L, Salgado AJ, Roybon L. Generation of an induced pluripotent stem cell line (CSC-44) from a Parkinson's disease patient carrying a compound heterozygous mutation (c.823C>T and EX6 del) in the PARK2 gene. Stem Cell Res. 2018 Mar;27:90-94. doi: 10.1016/j.scr.2018.01.006. Epub 2018 Jan 4. PMID: 29353703

115) Blauwendraat C, Kia DA, Pihlstrøm L, Gan-Or Z, Lesage S, Gibbs JR, Ding J, Alcalay RN, Hassin-Baer S, Pittman AM, Brooks J, Edsall C, Chung SJ, Goldwurm S, Toft M, Schulte C; International Parkinson's Disease Genomics Consortium (IPDGC), COURAGE-PD Consortium, Hernandez D, Singleton AB, Nalls MA, Brice A, Scholz SW, Wood NW. Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease. Neurobiol Aging. 2018 Apr;64:159.e5-159.e8. doi: 10.1016/j.neurobiolaging.2017.12.012. Epub 2017 Dec 20. PMID: 29398121

116) Marote A, Pomeshchik Y, Collin A, Goldwurm S, Lamas NJ, Pinto L, Salgado AJ, Roybon L. Generation of an induced pluripotent stem cell line (CSC-41) from a Parkinson's disease patient carrying a p.G2019S mutation in the LRRK2 gene. Stem Cell Res. 2018 Apr;28:44-47. doi: 10.1016/j.scr.2018.01.022. Epub 2018 Feb 2. PMID: 29414418

117) Perez Carrion M, Pischedda F, Biosa A, Russo I, Straniero L, Civiero L, Guida M, Gloeckner CJ, Ticozzi N, Tiloca C, Mariani C, Pezzoli G, Duga S, Pichler I, Pan L, Landers JE, Greggio E, Hess MW, Goldwurm S, Piccoli G. The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1. Front Mol Neurosci. 2018 Feb 28;11:64. doi: 10.3389/fnmol.2018.00064. eCollection 2018. PMID: 29541021.

118) Corrado L, De Marchi F, Tunesi S, Oggioni GD, Carecchio M, Magistrelli L, Tesei S, Riboldazzi G, Di Fonzo A, Locci C, Trezzi I, Zangaglia R, Cereda C, D'Alfonso S, Magnani C, Comi GP, Bono G, Pacchetti C, Cantello R,

Goldwurm S, Comi C. The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson's Disease. Front Neurol. 2018 Mar 29;9:213. doi: 10.3389/fneur.2018.00213. eCollection 2018.PMID: 29662465.

119) Mongelli A, Sarro L, Rizzo E, Nanetti L, Meucci N, Pezzoli G, Goldwurm S, Taroni F, Mariotti C, Gellera C. Multiple system atrophy and CAG repeat length: A genetic screening of polyglutamine disease genes in Italian patients.Neurosci Lett. 2018 Apr 30;678:37-42. doi: 10.1016/j.neulet.2018.04.044. [Epub ahead of print] PMID: 29715545

120) Romagnolo A, Fabbri M, Merola A, Montanaro E, Palermo S, Martone T, Seresini A, Goldwurm S, Rizzone MG, Lopiano L. Beyond 35 years of Parkinson's disease: a comprehensive clinical and instrumental assessment. J Neurol. 2018 Jun 26. doi: 10.1007/s00415-018-8955-z. [Epub ahead of print] PMID: 29943201

121) Blauwendraat C, Reed X, Kia DA, Gan-Or Z, Lesage S, Pihlstrøm L, Guerreiro R, Gibbs JR, Sabir M, Ahmed S, Ding J, Alcalay RN, Hassin-Baer S, Pittman AM, Brooks J, Edsall C, Hernandez DG, Chung SJ, Goldwurm S, Toft M, Schulte C, Bras J, Wood NW, Brice A, Morris HR, Scholz SW, Nalls MA, Singleton AB, Cookson MR; COURAGE-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease) Consortium, the French Parkinson's Disease Consortium, and the International Parkinson's Disease Genomics Consortium (IPDGC). Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA Neurol. 2018 Jul 23. doi: 10.1001/jamaneurol.2018.1885.